Aytu Biopharma (AYTU) EBIT (2010 - 2026)

Aytu Biopharma (AYTU) has 17 years of EBIT data on file, last reported at -$4.1 million in Q1 2026.

• EBIT for Q1 2026 came in at -$4.1 million, down 267.86% year-over-year; the trailing twelve-month figure through Mar 2026 was -$10.2 million (down 313.04% YoY), and the FY2025 annual result was -$2.9 million, down 82.09% from the prior year.
• EBIT retreated to -$4.1 million in Q1 2026 per AYTU's latest filing, from -$2.0 million in the prior quarter.
• Over five years, EBIT peaked at $69.8 million in Q2 2022 and troughed at -$53.4 million in Q1 2022.
• A 5-year average of $45823.5 and a median of -$1.7 million in 2024 frame the typical range for EBIT.
• The sharpest annual moves came in 2022 and 2026: EBIT surged 389.99% in 2022, then plunged 267.86% in 2026.
• A 5-year view of EBIT shows it stood at -$6.9 million in 2022, then jumped by 145.81% to $3.1 million in 2023, then plunged by 153.88% to -$1.7 million in 2024, then declined by 16.22% to -$2.0 million in 2025, then plunged by 106.29% to -$4.1 million in 2026.
• Business Quant data shows AYTU's EBIT at -$4.1 million in Q1 2026, -$2.0 million in Q4 2025, and -$1.5 million in Q3 2025.